Kalaris Therapeutics (KLRS) Cash from Financing Activities (2020 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Cash from Financing Activities of -$1.7 million for Q1 2026, down 101.58% year-over-year from $107.3 million in Q1 2025, and down 103.55% quarter-over-quarter from $47.7 million in Q4 2025.
Kalaris Therapeutics (KLRS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Kalaris Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$1.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 101.58% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at $46.0 million (down 61.57% YoY), while the FY2025 annual figure was $155.0 million, up 709.86% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$1.7 million, down from $47.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $126.4 million in Q3 2022, with the low at -$1.7 million in Q1 2026.
- The 5-year median for Cash from Financing Activities is $5.8 million (2024), against an average of $29.9 million.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities soared 68781.82% in 2024, then tumbled 101.58% in 2026.
- Kalaris Therapeutics' Cash from Financing Activities stood at $292000.0 in 2022, then tumbled by 96.23% to $11000.0 in 2023, then jumped by 68781.82% to $7.6 million in 2024, then surged by 530.06% to $47.7 million in 2025, then tumbled by 103.55% to -$1.7 million in 2026.
- Business Quant data shows KLRS's Cash from Financing Activities at -$1.7 million in Q1 2026, $47.7 million in Q4 2025, and $107.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -377,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -377,000.00 |
| Jun 30, 2026 | -377,000.00 |
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | 47.74 Mn |
| Dec 31, 2025 | 47.74 Mn |
| Mar 31, 2025 | 107.27 Mn |
| Mar 31, 2025 | 107.27 Mn |
| Dec 31, 2024 | 7.58 Mn |
| Dec 31, 2024 | 7.58 Mn |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 6.58 Mn |
| Mar 31, 2024 | 6.58 Mn |
| Dec 31, 2023 | 11,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 292,000.00 |
| Dec 31, 2022 | 292,000.00 |